Volume 3.48 | Dec 4

Hematopoiesis News 3.48 December 4, 2012
Hematopoiesis News

     In this issue: Publications | ReviewsIndustry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Hematopoiesis News on Twitter
TOP STORY
Ponatinib in Refractory Philadelphia Chromosome-Positive Leukemias
In this Phase I dose-escalation study, researchers enrolled 81 patients with resistant hematologic cancers, including 60 with chronic myeloid leukemia and five with Philadelphia chromosome-positive acute lymphoblastic leukemia. Ponatinib was administered once daily at doses ranging from 2 to 60 mg. [N Engl J Med] Abstract | Press Release

[Free On-Demand Webinar] Potential Applications of ALDH+ Cells in Regenerative Medicine - Watch Now.
PUBLICATIONS (Ranked by impact factor of the journal)

LABORATORY RESEARCH

Hematopoietic Stem Cell Survival and Transplantation Efficacy Is Limited by the BH3-Only Proteins Bim and Bmf
Based on the analysis of cytokine deprivation-induced changes in mRNA expression levels of Bcl-2 family proteins, scientists determined the consequences of BH3-only protein depletion on hematopoietic stem and progenitor cell survival in culture and, for selected candidates, on engraftment in vivo. [EMBO Mol Med]
Full Article

EKLF-Driven PIT1 Expression Is Critical for Mouse Erythroid Maturation In Vivo and In Vitro
Researchers demonstrated that Erythroid Krüppel-like Factor (EKLF) increases PIT1 expression during red blood cell maturation by binding to its promoter in vivo. They showed that shRNA-driven depletion of either PIT1 or EKLF impaired erythroid maturation of G1E cells in vitro, whereas re-expression of PIT1 in EKLF-depleted G1E cells partially restores erythroid maturation. [Blood] Abstract

MLL-AF9 Mediated Immortalization of Human Hematopoietic Cells along Different Lineages Changes during Ontogeny
The authors showed that depending on extrinsic cues, human neonatal CD34+ cells are readily immortalized along either the myeloid or lymphoid lineage upon MLL-AF9 expression and give rise to mainly lymphoid leukemia in immunocompromised mice. [Leukemia] Abstract

Identification of a Clonally Expanding Hematopoietic Compartment in Bone Marrow
Scientists showed with genetic labeling techniques, high-resolution imaging and functional experiments in mice that the periphery of the adult bone marrow cavity harbors previously unrecognized compartments with distinct properties. These units were composed of endothelial, hematopoietic and mesenchymal cells, were enriched in CD150+ CD48- putative hematopoietic stem cells, and enabled rapid hematopoietic cell proliferation and clonal expansion. [EMBO J] Abstract

Long-Term Type 1 Diabetes Influences Hematopoietic Stem Cells by Reducing Vascular Repair Potential and Increasing Inflammatory Monocyte Generation in a Murine Model
Investigators sought to determine the impact of long-standing type 1 diabetes on hematopoietic stem/progenitor cell number and function and to examine the impact of modulating glycoprotein 130 receptor in these cells. [Diabetologia] Abstract

Properties of Monocytes Generated from Hematopoietic CD34+ Stem Cells from Bone Marrow of Colon Cancer Patients
Scientists explored whether monocytes can be obtained from bone marrow hematopoietic CD34+ stem cells of colon cancer patients, using previously described protocol of expansion and differentiation to monocytes of cord blood-derived CD34+ hematopoietic progenitors. [Cancer Immunol Immunother] Full Article

CLINICAL RESEARCH

Rapid Mobilization of Cytotoxic Lymphocytes Induced by Dasatinib Therapy in Leukemia Patients
Using a collection of 55 leukemia patients treated with tyrosine kinase inhibitor (TKI) therapy investigators found that dasatinib, a second-generation broad-spectrum TKI, induced a rapid, dose-dependent and substantial mobilization of non-leukemic lymphocytes and monocytes in blood peaking 1 to 2 hours after an oral intake and the blood counts closely mirrored drug plasma concentration. [Leukemia] Abstract

Mobilization of Hematopoietic Progenitors from Normal Donors Using the Combination of GM-CSF And G-CSF Results in Fewer pDC in the Graft and Enhanced Donor T-Cell Engraftment with Th1-Polarization: Results from a Randomized Clinical Trial
To test the hypothesis that the content of plasmacytoid dendritc cells (pDC) in an allograft can be modulated with the cytokines used for mobilization, the authors randomized the HLA-matched sibling donors of 50 patients with hematological malignancies to a mobilization regimen of either Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) and Granulocyte-Colony-Stimulating Factor (G-CSF) or G-CSF alone. [Biol Blood Marrow Transplant] Abstract

Folinic Acid Supplementation in Higher Doses Is Associated with Graft Rejection in Pediatric Hematopoietic Stem Cell Transplantation
In this is single-center retrospective study researchers investigated folinic acid administration in 87 children undergoing stem cell transplantation between 2007 and 2010. [Biol Blood Marrow Transplant] Abstract

Complimentary Wallchart: Human Hematopoietic Progenitors. Request Your Copy Today.

REVIEWS
Hematopoietic Stem Cell Therapy for Multiple Sclerosis: Top Ten Lessons Learned
The top ten lessons learned from the growing experience using hematopoietic stem cell transplants for the treatment of multiple sclerosis are discussed. [Neurotherapeutics] Full Article
INDUSTRY NEWS

Fate Therapeutics Initiates Phase II Clinical Study of ProHema for the Treatment of Hematologic Malignancies
Fate Therapeutics, Inc. announced the initiation of a randomized, controlled, Phase II multi-center study of its investigational hematopoietic stem cell therapy, ProHema, in adult patients undergoing double umbilical cord blood transplantation for hematologic malignancy. [Fate Therapeutics, Inc.] Press Release

IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
IntelliCell BioSciences, Inc. announced that it has entered a sponsored research agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey. Under terms of the agreement, the New Jersey Center for Biomaterials will be conducting a series of research projects that will further define the unique characteristics and properties of IntelliCell’s proprietary cellular population. [PR Newswire Association LLC] Press Release

POLICY NEWS

National Institutes of Health (United States)

Food and Drug Administration (United States)
 
Center for Biologics Evaluation and Research (United States)
 
European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS

NEW Canadian Blood and Marrow Transplant Group 2013 Conference
April 10-12, 2013
Winnipeg, Canada

Visit our events page to see a complete list of events in the hematopoietic community.

JOB OPPORTUNITIES

Product Quality Scientist (STEMCELL Technologies, Inc.)

Scientist – Endothelial Cell Research (STEMCELL Technologies, Inc.)

Research Technologist – Cell Separation (STEMCELL Technologies, Inc.)

Scientist or Engineer – hPSC Bioengineer (STEMCELL Technologies, Inc.)

Quality Control Analyst (STEMCELL Technologies, Inc.)

Postdoctoral Position – Tumor Stem Cells (Cancer Institute of New Jersey)

Senior Lecturer – Cancer Stem Cells (The European Cancer Stem Cell Research Institute)

Postdoctoral Position – Hematopoietic Stem Cell and Leukemia Research (City of Hope Beckman Research Institute) 

Assistant Professor – Myelodysplastic Syndromes (MD Anderson Cancer Center)

Postdoctoral Position – Extension of the Hough Transform and Applications to the Imaging of the Hematopoietic System (Università degli Studi di Genova)


Recruit Top Talent: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Hematopoiesis Cell News: Archives | Events | Contact Us

Suite 201 – 375 West Fifth Avenue
Vancouver, BC V5Y 1J6, Canada